KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBIT (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of EBIT data on record, last reported at $17.4 million in Q4 2025.

  • For Q4 2025, EBIT rose 175.3% year-over-year to $17.4 million; the TTM value through Dec 2025 reached $104.8 million, up 93.39%, while the annual FY2025 figure was $104.8 million, 93.39% up from the prior year.
  • EBIT reached $17.4 million in Q4 2025 per ACAD's latest filing, down from $35.8 million in the prior quarter.
  • Across five years, EBIT topped out at $132.7 million in Q4 2022 and bottomed at -$113.0 million in Q1 2022.
  • Average EBIT over 5 years is $3.4 million, with a median of $9.1 million recorded in 2023.
  • The widest YoY moves for EBIT: up 902.21% in 2024, down 123.66% in 2024.
  • A 5-year view of EBIT shows it stood at $90.6 million in 2021, then surged by 46.47% to $132.7 million in 2022, then fell by 26.45% to $97.6 million in 2023, then crashed by 123.66% to -$23.1 million in 2024, then surged by 175.3% to $17.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were $17.4 million in Q4 2025, $35.8 million in Q3 2025, and $32.4 million in Q2 2025.